Overview
KZIA market data
Price History
KZIA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.24 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -9,259.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.86 – $17.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $146.2M · P/S 841.23.
Company News
Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29Benzinga · Aug 13, 2026, 4:31 PM
Kazia Therapeutics Files Provisional Patent Application Supporting Therapeutic Strategy Designed To Prevent Metastatic Recurrence In Patients With High-Risk Early-Stage Triple-Negative Breast CancerBenzinga · Jul 28, 2026, 11:35 AM
BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price TargetBenzinga · Jul 15, 2026, 5:20 PM
BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34Benzinga · Jul 1, 2026, 11:45 AM
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsightGlobenewswire Inc · Jun 16, 2026, 5:15 PM
Lake Street Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $32Benzinga · Jun 11, 2026, 2:53 PM
Kazia Therapeutics Appoints James Levine as Chief Financial OfficerBenzinga · Jun 2, 2026, 12:15 PM
Kazia Therapeutics Appoints James Levine As CFO, Effective June 1Benzinga · Jun 2, 2026, 11:39 AM
Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsightGlobenewswire Inc · May 27, 2026, 5:15 PM
Kazia Therapeutics Expands Enrollment In Phase 1b Trial For Breast Cancer Treatment PaxalisibBenzinga · May 26, 2026, 11:36 AM